RxDoctor Payments Data

Hugo Quintana, MD

Cardiovascular Disease · Pascagoula, MSNPI 1124043641

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.0%), travel and lodging and other — rather than concentrated in one kind of arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 20.1%. 2025 is the largest year on record at $13,988, 3.0 times the $4,733 reported in 2019. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,660in general payments, 2019–2025

Across 818 payments — averaging $58.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$10K
  • Angiodynamics, Inc.$8K
  • Medtronic$6K
  • Boston Scientific$5K
  • Edwards Lifesciences$4K
  • Abbott$2K
  • plus $11K from 37 others

What the payments were for

  • Speaking & faculty fees$2,4005%
  • Travel & lodging$14,38830%
  • Food & beverage$22,41847%
  • Education$460%
  • Gifts$750%
  • Other$8,33317%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,660 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$653,980
Medicare patients
1,282
Services billed
6,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban866$814,758
XareltoRivaroxaban311$307,227
EntrestoSacubitril/Valsartan330$297,930
Repatha SureclickEvolocumab65$49,410
JardianceEmpagliflozin42$39,859
FarxigaDapagliflozin Propanediol22$29,835
BrilintaTicagrelor36$27,287
NexletolBempedoic Acid17$16,388
ClopidogrelClopidogrel Bisulfate1,193$13,988
NexlizetBempedoic Acid/Ezetimibe23$13,830
Valsartan332$10,391
EdarbiAzilsartan Medoxomil23$9,187
Propafenone Hcl ErPropafenone Hcl43$8,034
Diltiazem 12hr ErDiltiazem Hcl29$7,817
Propafenone Hcl148$7,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$500$814,758866 claims
Johnson & JohnsonXarelto$638$307,227311 claims
NovartisEntresto$528$297,930330 claims
AstraZenecaFarxiga, Brilinta$190$57,12358 claims
Boehringer IngelheimJardiance$400$39,85942 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$53$30,21840 claims
Arbor Pharmaceuticals, Inc.Edarbi$148$9,18723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →